The phase 3 CheckMate-816 trial establishes a new standard of care for resectable non–small-cell lung cancer (NSCLC): neoadjuvant nivolu­mab (Opdivo) plus chemotherapy. Read More ›

2022 Midyear Review: Non–Small-Cell Lung Cancer

Anxiety and depression in patients with advanced lung cancer are associated with poor outcomes when untreated. Radiotherapy, breathlessness, and fatigue are among top predictors of these debilitating conditions. Read More ›

Study evaluates factors that may help determine whether a patient with advanced non–small-cell lung cancer may benefit from the use of immune checkpoint inhibitors. Read More ›

In patients with non–small-cell lung cancer, KRAS G12C mutation is associated with female sex, smoking, and adenocarcinoma and the risk of development of central nervous system metastasis. Read More ›

Analysis reveals factors associated with the development of immune-related adverse events in patients with advanced non–small-cell lung cancer treated with immunotherapy. Read More ›

Recent survey results of physicians who treat patients with non–small-cell lung cancer reveal high biomarker testing rates, but treatment decisions frequently depend on test result turnaround time. Read More ›

Newly diagnosed patients who adhered to tumor board recommendations for treatment have a longer overall survival time than patients who only partially adhered or did not adhere to recommendations. Read More ›

Patients with KRAS G12C non–small-cell lung cancer appear to have improved progression-free survival before immunotherapy than patients with non-KRAS G12C lung cancer, but there was no improvement in overall survival between the 2 groups. Read More ›

More severe interstitial lung disease with more severe radiological features was found on second occurrence in patients with lung cancer who were rechallenged with ICI treatment. Read More ›

Page 4 of 23

Subscribe Today!

To sign up for our newsletter or print publications, please enter your contact information below.

I'd like to receive: